Kite Logo
Find a Treatment Center
Investor Relations
Contact Us
KiteKonnect®
Gilead Logo
  • About Us
    Our Mission Our Story Therapeutic Areas Leadership Kite Locations
  • Science & Medicine
    Our Technology Our Therapies Pipeline Trials & Expanded Access External Research Program (ERP)
  • Newsroom
    Newsroom Press Releases Company Statements Media Kit
  • Careers
    Now Hiring Careers at Kite Manufacturing Careers at Kite Early Talent Programs at Kite Culture & Benefits
  • Utility
    Contact Us KiteKonnect®
BACK TO MAIN MENU Company Statements Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma Kite Announces U.S. FDA Clearance of Investigational
  • Find a Treatment Center
  • Investor Relations
Toggle Inner Dropdown
BACK TO MAIN MENU Google.com

Media Kit

View our media materials:

Non-Hodgkin Lymphoma

Understanding Chimeric Antigen Receptor (CAR) T Cell Technology

Kite Logo

AREAS OF INTEREST

  • Our Mission
  • Our Technology
  • Pipeline
  • Careers at Kite

INFORMATION

  • Contact Us
  • Newsroom
  • Investors
  • KiteKonnect.com
  • Gilead.com
  • Sitemap

LEGAL

  • Privacy Policy
  • Terms and Conditions
  • Compliance Program
  • Social Media Guidelines

FOLLOW US

  • LinkedIn Logo
  • Twitter Logo

© 2017-2022 Gilead Sciences, Inc. All rights reserved.

For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483)